Analyst Firm Raises Target for Newron Following Clinical and Financial Updates

Analyst boosts Newron target to CHF 48, citing strong cash and key 2026 schizophrenia trial data. Firm secured funding and new patent, despite 2025 net loss.

H.C. Wainwright has increased its price target for biopharmaceutical company Newron SpA from CHF 43 to CHF 48. This reassessment is driven by advancements in the firm's clinical pipeline and a strengthened financial position that extends through the end of 2027. The timing of this upgrade is significant, as pivotal data from a key Phase III program is anticipated before the close of the current year.

Financial Position and Leadership Changes

Newron reported a net loss of EUR 13.2 million for the 2025 fiscal year, a shift from the prior year's net profit of EUR 15.8 million. This change is attributed to increased development expenditures ahead of critical late-stage trials. Despite the loss, the company's liquidity is secure. A capital raise in February 2026 generated EUR 15 million, with an additional EUR 11 million expected to be drawn down from existing financing agreements before year-end.

Leadership is also undergoing a transition. Dr. Chris Martin has assumed the role of Chairman of the Board of Directors, succeeding Dr. Ulrich Köstlin. Further governance changes are scheduled for the Annual General Meeting on April 23, 2026. The board has proposed the appointment of George Garibaldi and Paolo Zocchi as new independent directors. They are slated to replace Patrick Langlois and Luca Benatti, who are stepping down after lengthy tenures.

Evenamide Approaches Key Clinical Milestones

The core of the analyst's revised valuation is the ENIGMA-TRS program, which comprises two separate Phase III studies investigating the treatment of therapy-resistant schizophrenia. Initial results from both trials are expected in 2026. Concurrently, a dedicated Phase III study by Newron's Japanese partner, EA Pharma—a subsidiary of the Eisai Group—has been underway since January 2026. In a further boost, the European Patent Office granted substance protection for Evenamide in early 2026, extending exclusivity to 2044.

The current analyst consensus price target stands at approximately CHF 47.94. Compared to a recent share price around CHF 15.20, this implies substantial potential upside. Some financial models maintain a degree of caution, however, noting that Phase III data readouts are inherently uncertain.